GRCE / Grace Therapeutics, Inc. - Depositi SEC, Relazione annuale, dichiarazione di delega

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2026 GRACE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission

Corporate Presentation April 2026 Summary 2 Forward Looking Statements Statements in this presentation that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Lit

Exhibit 99.1 Corporate Presentation April 2026 Summary 2 Forward Looking Statements Statements in this presentation that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange

Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104 FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, and Controls and Non-Clinical Information FDA Does not Request Additio

Exhibit 99.1 Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104 FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, and Controls and Non-Clinical Information FDA Does not Request Additional Clinical Data Company Intends to Resubmit Application Following Resolution of Cited Items Princeton, NJ, April 23, 2026 (GLOBE NEWSWI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2026 GRACE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2026 GRACE THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2026 GRACE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) State of Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation)

Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update

Exhibit 99.1 Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Phase 3 STRIVE-ON Safety Trial Data Presented at 2025 Society of Vascular and Interventional Neurology Annual Mee

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 Grace

1

Exhibit 10.3 January 10, 2026 PRIVATE AND CONFIDENTIAL Amresh Kumar Dear Amresh: This letter serves to modify and amend the Letter Agreement (“Letter Agreement”) dated as of November 12, 2025, between you and Grace Therapeutics, Inc. (“Company”) containing the terms and conditions of your employment as Vice President, Program Management of the Company. This amendment (“Amendment No. 1”) will be ef

1

Exhibit 10.1 January 10, 2026 PRIVATE AND CONFIDENTIAL Prashant Kohli Dear Prashant: This letter serves to modify and amend the Letter Agreement (“Letter Agreement”) dated as of August 12, 2024, between you and Grace Therapeutics, Inc. (“Company”), as amended pursuant to that amendment dated November 12, 2025 (“Amendment No. 1”), containing the terms and conditions of your employment as Chief Exec

1

Exhibit 10.5 January 10, 2026 PRIVATE AND CONFIDENTIAL R. Loughlin Macdonald Dear Loch: This letter serves to modify and amend the Letter Agreement (“Letter Agreement”) dated as of November 12, 2025, between you and Grace Therapeutics, Inc. (“Company”) containing the terms and conditions of your employment as Chief Medical Officer of the Company. This amendment (“Amendment No. 1”) will be effectiv

1

Exhibit 10.2 January 10, 2026 PRIVATE AND CONFIDENTIAL Robert J. DelAversano Dear Robert: This letter serves to modify and amend the Letter Agreement (“Letter Agreement”) dated as of November 12, 2025, between you and Grace Therapeutics, Inc. (“Company”) containing the terms and conditions of your employment as Vice President, Finance, Principal Financial and Accounting Officer of the Company. Thi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2026 GRACE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commissi

1

Exhibit 10.4 January 10, 2026 PRIVATE AND CONFIDENTIAL Carrie D’Andrea Dear Carrie: This letter serves to modify and amend the Letter Agreement (“Letter Agreement”) dated as of November 12, 2025, between you and Grace Therapeutics, Inc. (“Company”) containing the terms and conditions of your employment as Vice President, Clinical Operations of the Company. This amendment (“Amendment No. 1”) will b

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file num

1

Exhibit 10.1 November 12, 2025 PRIVATE AND CONFIDENTIAL Prashant Kohli Dear Prashant: This letter serves to modify and amend the Letter Agreement (“Letter Agreement”) dated as of August 12, 2024, between you and Grace Therapeutics, Inc. (“Company”) containing the terms and conditions of your employment as Chief Executive Officer of the Company. This amendment (“Amendment No. 1”) will be effective

1

Exhibit 10.5 November 12, 2025 PRIVATE AND CONFIDENTIAL R. Loughlin Macdonald Dear Loch: This Letter Agreement (“Letter Agreement”) sets forth the terms and conditions of your employment with Grace Therapeutics, Inc. (“Company”), and supersedes in its entirety the Offer Letter between you and the Company, dated May 10, 2024. Title: Chief Medical Officer Reporting to: Prashant Kohli, Chief Executiv

1

Exhibit 10.3 November 12, 2025 PRIVATE AND CONFIDENTIAL Amresh Kumar Dear Amresh: This Letter Agreement (“Letter Agreement”) sets forth the terms and conditions of your employment with Grace Therapeutics, Inc. (“Company”), and supersedes in its entirety the Offer Letter between you and the Company, dated May 11, 2023. Title: Vice President, Program Management Reporting to: Prashant Kohli, Chief Ex

Corporate Presentation Fall 2025 Summary 2 Forward Looking Statements Statements in this presentation that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Liti

Exhibit 99.2 Corporate Presentation Fall 2025 Summary 2 Forward Looking Statements Statements in this presentation that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2025 GRACE THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2025 GRACE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) State of Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation)

Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update Announced U.S. Food and Drug Administration (FDA) Acceptance for Review of New Drug Application (NDA) for GTx-104 FDA Established April 23, 2026 as PDUFA Tar

Exhibit 99.1 Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update Announced U.S. Food and Drug Administration (FDA) Acceptance for Review of New Drug Application (NDA) for GTx-104 FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH

1

Exhibit 10.4 November 12, 2025 PRIVATE AND CONFIDENTIAL Carrie D’Andrea Dear Carrie: This Letter Agreement (“Letter Agreement”) sets forth the terms and conditions of your employment with Grace Therapeutics, Inc. (“Company”), and supersedes in its entirety the Offer Letter between you and the Company, dated June 21, 2023. Title: Vice President, Clinical Operations Reporting to: Prashant Kohli, Chi

1

Exhibit 10.2 November 12, 2025 PRIVATE AND CONFIDENTIAL Robert J. DelAversano Dear Robert: This Letter Agreement (“Letter Agreement”) sets forth the terms and conditions of your employment with Grace Therapeutics, Inc. (“Company”), and supersedes in its entirety the Offer Letter between you and the Company, dated November 21, 2023. Title: Vice President, Finance, Principal Financial and Accounting

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 Grace

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2025 GRACE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commissi

Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review

Exhibit 99.1 Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review Princeton, NJ, October 23, 2025 (GLOBE NEWSWIRE)—Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2025 GRACE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commis

Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104 Grant of First Method of Use Patent Adds New Pillar to Grace’s Multi-layered Intellectual Property and Potential Market Exclusivity Protection Patent Coverage Exten

Exhibit 99.1 Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104 Grant of First Method of Use Patent Adds New Pillar to Grace’s Multi-layered Intellectual Property and Potential Market Exclusivity Protection Patent Coverage Extended to 2043 Princeton, NJ, September 18, 2025 (GLOBE NEWSWIRE)—Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2025 GRACE THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2025 GRACE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) State of Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2025 GRACE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commissio

Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104 FDA Establishes April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Pat

Exhibit 99.1 Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104 FDA Establishes April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Supported by Positive Results from Phase 3 STRIVE-ON Safe

Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for GTx-104 Seeking Approval of GTx-104 in the Treatment of Patients with

Exhibit 99.1 Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for GTx-104 Seeking Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) NDA Supported by Data from Phase 3 STRIVE-ON Safety Trial, which Met Primary Endpoint and Provi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 GRACE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) State of Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 Grace Ther

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104 Submission Seeks Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Packa

Exhibit 99.1 Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104 Submission Seeks Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Includes Positive Results from Phase 3 STRIVE-ON Safety Trial of GTx-104 Submission Has the Potential to Trigger Exercise of up to $7.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 GRACE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission

Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update Held Type C meeting with FDA on Planned New Drug Application (NDA) Submission, Including Clinical, Non-clinical, and Chemistry, Manufacturing, and Control (CMC) Requi

Exhibit 99.1 Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update Held Type C meeting with FDA on Planned New Drug Application (NDA) Submission, Including Clinical, Non-clinical, and Chemistry, Manufacturing, and Control (CMC) Requirements NDA On Track for Submission to FDA in First Half of Calendar 2025 NDA to be Supported by Data from Phase 3 STRIVE-ON Safety Trial

List of Subsidiaries

Exhibit 21.1 Grace Therapeutics, Inc. LIST OF SUBSIDIARIES Name Jurisdiction of Incorporation Percent Owned Grace Therapeutics U.S., Inc. (formerly Acasti Pharma U.S., Inc.) Delaware, United States 100%

Grace Therapeutics, Inc. Insider Trading Policy

Exhibit 19.1 GRACE THERAPEUTICS, INC. INSIDER TRADING POLICY Last updated: June 21, 2025 INTRODUCTION U.S. federal and state laws prohibit buying, selling, gifting, or making other transfers of securities by persons who have material information that is not generally known or available to the public. These laws also prohibit persons with such Material Nonpublic Information (as defined herein) from

Employment Agreement by and between Carrie D’Andrea and the Company, dated July 1, 2023

Exhibit 10.11 June 21, 2023 PRIVATE AND CONFIDENTIAL DELIVERED BY EMAIL Carrie D’Andrea Dear Carrie: We are pleased to extend the following offer of employment with Acasti Pharma Inc. (“Acasti”): Title: Vice President, Clinical Operations Reporting to: Prashant Kohli, Chief Executive Officer Base Salary: Annualized base salary of $275,000, less applicable deductions and withholdings. Annual Bonus:

Grace Therapeutics, Inc. Incentive Compensation Recoupment Policy

Exhibit 97.1 Grace Therapeutics, Inc. Incentive Compensation Recovery Policy Adopted by the Board of Directors (the “Board”) of Grace Therapeutics, Inc. (the “Company”) on November 10, 2023 The Company is committed to conducting business in accordance with the highest ethical and legal standards, and the Board believes that a culture that emphasizes integrity and accountability is in the best inte

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 Grace Therapeutic

Employment Agreement by and between R. Loch Macdonald and the Company, dated May 7, 2024

Exhibit 10.18 May 7, 2024 PRIVATE AND CONFIDENTIAL DELIVERED BY EMAIL R. Loch Macdonald Dear Loch: We are pleased to extend the following offer of employment with Acasti Pharma Inc. (“Acasti”): Title: Chief Medical Officer (CMO) Reporting to: Prashant Kohli, Chief Executive Officer Base Salary: Annualized base salary of $200,000, less applicable deductions and withholdings. Annual Bonus: You will

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 GRACE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) State of Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Co

Description of Securities

Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Annual Report on Form 10-K of which this exhibit forms a part, the only class of securities of Grace Therapeutics, Inc. (“we,” “us” and “our”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), is our com

Form of Indemnification Agreement between Grace Therapeutics, Inc. and its directors and officers

Exhibit 10.12 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of , 20 by and between Grace Therapeutics, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement. RECITALS WHEREAS, the Board of Directors o

Employment Agreement by and between Amresh Kumar and the Company, dated May 8, 2023

Exhibit 10.10 May 3, 2023 (revised on May 11, 2023) PRIVATE AND CONFIDENTIAL DELIVERED BY EMAIL Amresh Kumar Dear Amresh: We are pleased to extend the following offer of employment with Acasti Pharma Inc. (“Acasti”): Title: Vice President, Program Management Reporting to: Prashant Kohli, Chief Executive Officer Base Salary: Annualized base salary of $275,000, less applicable deductions and withhol

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2025 GRACE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) State of Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Co

Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104 NDA Submission Anticipated Q2 Calendar 2025

Exhibit 99.1 Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104 NDA Submission Anticipated Q2 Calendar 2025 Princeton, NJ, April 9, 2025 (GLOBE NEWSWIRE)—Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being

GRACE THERAPEUTICS, INC. 103 Carnegie Center, Suite 300 Princeton, New Jersey 08540

GRACE THERAPEUTICS, INC. 103 Carnegie Center, Suite 300 Princeton, New Jersey 08540 March 12, 2025 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jason Drory Re: Grace Therapeutics, Inc. Registration Statement on Form S-3 Filed March 10, 2025 File No. 333-285661 Request for Acceleration

LETTER

March 11, 2025 Prashant Kohli Chief Executive Officer Grace Therapeutics, Inc. 103 Carnegie Center, Suite 300 Princeton, NJ 08540 Re: Grace Therapeutics, Inc. Registration Statement on Form S-3 Filed March 10, 2025 File No. 333-285661 Dear Prashant Kohli: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding req

As filed with the Securities and Exchange Commission on March 10, 2025

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 10, 2025 Registration Statement No.

Calculation of Filing Fee Tables Form S-3 (Form Type) Grace Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Grace Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 GRACE THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 GRACE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) State of Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Co

Corporate Presentation March 2025 Summary 2 Forward Looking Statements Statements in this presentation that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Lit

Exhibit 99.1 Corporate Presentation March 2025 Summary 2 Forward Looking Statements Statements in this presentation that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numb

Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update

Exhibit 99.1 Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug Application (NDA) Submission Anticipated First Half of Calendar 2025 Secured Private Placement Financing of $15 Million in Upfront Gross Procee

Form of 2024 Incentive Stock Option Award Agreement under the Grace Therapeutics, Inc. 2024 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on February 13, 2025)

Exhibit 10.2 Grant No. GRACE Therapeutics, INC. 2024 EQUITY INCENTIVE PLAN Incentive STOCK OPTION AGREEMENT COVER SHEET Grace Therapeutics, Inc., a Delaware corporation (the “Company”), hereby grants an option (the “Option”) to purchase shares of its common stock, par value $0.0001 per share (the “Common Stock”), to the Grantee named below, subject to the vesting and other conditions set forth bel

Grace Therapeutics, Inc. 2024 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Company’s the Quarterly Report on Form 10-Q filed with the SEC on February 13, 2025)

Exhibit 10.1 GRACE THERAPEUTICS, INC. 2024 EQUITY INCENTIVE PLAN 1. PURPOSE The Plan is intended to (a) provide eligible persons with an incentive to contribute to the success of the Company and to operate and manage the Company’s business in a manner that will provide for the Company’s long-term growth and profitability to benefit its stockholders and other important stakeholders, including its e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 Grace

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2025 GRACE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) State of Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation)

Form of 2024 Non-Qualified Stock Option Award Agreement under the Grace Therapeutics, Inc. 2024 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on February 13, 2025)

Exhibit 10.3 Grant No. GRACE Therapeutics, INC. 2024 EQUITY INCENTIVE PLAN Nonqualified STOCK OPTION AGREEMENT COVER SHEET Grace Therapeutics, Inc., a Delaware corporation (the “Company”), hereby grants an option (the “Option”) to purchase shares of its common stock, par value $0.0001 per share (the “Common Stock”), to the Grantee named below, subject to the vesting and other conditions set forth

Form of Warrant to Purchase Common Warrants or Pre-Funded Warrants (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed with the SEC on February 10, 2025)

Exhibit 4.2 THIS WARRANT AND THE SHARES OF COMMON STOCK OR PRE-FUNDED WARRANTS ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH S

Form of Non-Placement Agent Securities Purchase Agreement (incorporated by reference to Exhibit 10.2 to the

Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of February 10, 2025, by and among Grace Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are executing and deliveri

Corporate Presentation February 2025 Summary 2 Forward Looking Statements Statements in this presentation that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities

Exhibit 99.2 Corporate Presentation February 2025 Summary 2 Forward Looking Statements Statements in this presentation that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Excha

Form of Placement Agent Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the C

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of February 10, 2025, by and among Grace Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are executing and deliveri

Form of Pre-Funded Warrant, dated February 11, 2025 (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on February 10, 2025)

Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN

Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Application (NDA)

Exhibit 99.1 Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Application (NDA) Submission Expected in the First Half of 2025 Princeton, NJ, February 10, 2025 (GLOBE NEWSWIRE)—Grace Therapeutics, Inc. (Nasdaq: GRCE),

Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed with the SEC on February 10, 2025)

Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of February 10, 2025, is entered into by and among Grace Therapeutics, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2025 GRACE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commiss

Grace Therapeutics Announces Private Placement Financing of up to $30 Million Financing led by Nantahala Capital and ADAR1 Partners, LP with participation from new and existing healthcare-focused institutional investors $15 million in upfront gross p

Exhibit 99.3 Grace Therapeutics Announces Private Placement Financing of up to $30 Million Financing led by Nantahala Capital and ADAR1 Partners, LP with participation from new and existing healthcare-focused institutional investors $15 million in upfront gross proceeds with the potential to receive up to an additional $15 million in potential warrant exercise proceeds for an aggregate of up to ap

LIMITED POWER OF ATTORNEY BANK OF AMERICA CORPORATION

EX-99 2 bacpoa.htm BANK OF AMERICA CORPORATION LIMITED POWER OF ATTORNEY BANK OF AMERICA CORPORATION, a Delaware corporation (the "Corporation" ), does hereby make, constitute, and appoint each of Marie Andre, Andres Ortiz Custodio, Kamil Dziedzic, Valerie Ezeagbo, Kelvin Kwo k, Frank Lui, James Todd, Ben Tsoi, Michelle Wong, and Monica Yako as an attorney-in-fact for the Corporation acting for th

ACST / Grace Therapeutics, Inc. / BANK OF AMERICA CORP /DE/ Passive Investment

SC 13G/A 1 doc1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 01)* GRACE THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00439U104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru

ACST / Grace Therapeutics, Inc. / ADAR1 Capital Management, LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Grace Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00430K865 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate

UNITED STATES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 Grace

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 GRACE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) State of Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation)

Grace Therapeutics Announces Second Fiscal Quarter 2025 Financial Results, Provides Business Update

Exhibit 99.1 Grace Therapeutics Announces Second Fiscal Quarter 2025 Financial Results, Provides Business Update STRIVE-ON Data Readout Expected First Calendar Quarter 2025; NDA Submission on Track for 1H Calendar 2025 Completed Corporate Re-Branding, Connecting Company to Rich Scientific Legacy of Grace Therapeutics Announced Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Tr

Bylaws of Grace Therapeutics, Inc. (incorporated by refence to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed with the SEC on October 28, 2024)

Exhibit 3.2 BYLAWS OF GRACE THERAPEUTICS, INC. ARTICLE I. OFFICES Section 1.01 Registered Office. The registered office and registered agent of Grace Therapeutics, Inc. (the “Corporation”) in the State of Delaware shall be as set forth in the Corporation’s certificate of incorporation as then in effect (as the same may be amended and/or restated from time to time, the “Certificate of Incorporation

UNITED STATES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2024 GRACE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commissi

Certificate of Amendment to the Certificate of Incorporation of Grace Therapeutics, Inc. (incorporated by refence to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on October 28, 2024)

Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF ACASTI PHARMA INC. Acasti Pharma Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: FIRST: That the first Article of the Certificate of Incorporation of the Corporation (the “Certificate of Incorporation”) is hereby amended and restated in it

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2024 ACASTI PHARMA INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission Fil

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc. Name Change Reflects Extensive Scientific and Corporate Brand Equity Previously Established under Grace Therapeutics Grace Therapeutics will begin trading on Nasdaq under the trading

Exhibit 99.1 Acasti Announces Corporate Name Change to Grace Therapeutics, Inc. Name Change Reflects Extensive Scientific and Corporate Brand Equity Previously Established under Grace Therapeutics Grace Therapeutics will begin trading on Nasdaq under the trading symbol "GRCE" effective October 28, 2024 Virtual Key Opinion Leader Event to be held on November 20th Princeton, NJ, October 25, 2024 (GL

As filed with the Securities and Exchange Commission on October 8, 2024

As filed with the Securities and Exchange Commission on October 8, 2024 Registration No.

As filed with the Securities and Exchange Commission on October 8, 2024

As filed with the Securities and Exchange Commission on October 8, 2024 Registration No.

As filed with the Securities and Exchange Commission on October 8, 2024

As filed with the Securities and Exchange Commission on October 8, 2024 Registration No.

As filed with the Securities and Exchange Commission on October 8, 2024

As filed with the Securities and Exchange Commission on October 8, 2024 Registration No.

As filed with the Securities and Exchange Commission on October 8, 2024

As filed with the Securities and Exchange Commission on October 8, 2024 Registration No.

Table 1: Newly Registered Securities

Calculation of Filing Fee Tables S-8 Acasti Pharma Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value $0.0001 per share Other 1,350,000 $ 2.91 $ 3,928,500.00 0.0001531 $ 601.45 Total Offering

As filed with the Securities and Exchange Commission on October 8, 2024

As filed with the Securities and Exchange Commission on October 8, 2024 Registration Statement No.

ACASTI PHARMA INC. ARTICLE I.

EXHIBIT 3.4 BYLAWS OF ACASTI PHARMA INC. ARTICLE I. OFFICES Section 1.01 Registered Office. The registered office and registered agent of Acasti Pharma Inc. (the “Corporation”) in the State of Delaware shall be as set forth in the Corporation’s certificate of incorporation as then in effect (as the same may be amended and/or restated from time to time, the “Certificate of Incorporation”). Section

Certificate of Incorporation of Grace Therapeutics, Inc. (incorporated by reference to Exhibit 3.3 to the Company’s Current Report on Form 8-K filed with the SEC on October 7, 2024)

EXHIBIT 3.3 CERTIFICATE OF INCORPORATION OF ACASTI PHARMA INC. I, the undersigned, for the purposes of incorporating and organizing a corporation under the General Corporation Law of the State of Delaware, do execute this Certificate of Incorporation and do hereby certify as follows: ARTICLE I The name of the corporation (the “Corporation”) is Acasti Pharma Inc. ARTICLE II The address of the regis

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2024 ACASTI PHARMA INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File

ARTICLES ACASTI PHARMA INC. (the “Company”)

EXHIBIT 3.2 Incorporation number: C1504591 ARTICLES of ACASTI PHARMA INC. (the “Company”) TABLE OF CONTENTS 1. INTERPRETATION 1 1.1 Definitions 1 1.2 Business Corporations Act and Interpretation Act Definitions Applicable 2 2. SHARES AND SHARE CERTIFICATES 2 2.1 Authorized Share Structure 2 2.2 Form of Share Certificate 2 2.3 Shareholder Entitled to Certificate or Acknowledgement 2 2.4 Delivery by

CERTIFIED COPY Of a Document filed with the Province of British Columbia Registrar of Companies

Exhibit 3.1 Mailing Address: Location: PO Box 9431 Stn Prov Govt 2nd Floor - 940 Blanshard Street Victoria BC V8W 9V3 Victoria BC www.corporateonline.gov.bc.ca 1 877 526-1526 CERTIFIED COPY Of a Document filed with the Province of British Columbia Registrar of Companies Notice of Articles BUSINESS CORPORATIONS ACT T.K. SPARKS This Notice of Articles was issued by the Registrar on: October 1, 2024

Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on October 7, 2024)

Exhibit 4.1 THIS CERTIFIES THAT is the owner of DATED COUNTERSIGNED AND REGISTERED: COMPUTERSHARE TRUST COMPANY, N.A. TRANSFER AGENT AND REGISTRAR, FULLY-PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF Acasti Pharma Inc. (hereinafter called the “Company”), transferable on the books of the Company in person or by duly authorized attorney, upon surrender of this Certificate properly endorsed. This

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 ACASTI PHARMA INC. (Exact Name of Registrant as Specified in its Charter) Québec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission Fil

ACASTI PHARMA INC. 2024 EQUITY INCENTIVE PLAN

EXHIBIT 10.1 ACASTI PHARMA INC. 2024 EQUITY INCENTIVE PLAN 1. PURPOSE The Plan is intended to (a) provide eligible persons with an incentive to contribute to the success of the Company and to operate and manage the Company’s business in a manner that will provide for the Company’s long-term growth and profitability to benefit its stockholders and other important stakeholders, including its employe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2024 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission Fil

Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104 Data Readout Expected Early Calendar 2025; NDA Submission on Track for 1H Calendar 2025

Exhibit 99.1 Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104 Data Readout Expected Early Calendar 2025; NDA Submission on Track for 1H Calendar 2025 Princeton, NJ, September 25, 2024 (GLOBE NEWSWIRE)- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) ☐ Definitive Proxy Statem

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File N

Letter Agreement by and between Prashant Kohli and the Company, dated August 12, 2024.

Exhibit 10.1 August 12, 2024 PRIVATE AND CONFIDENTIAL Prashant Kohli 31 Northrup Court, Newtown, PA 18940 [email protected] Dear Prashant: This Letter Agreement (“Letter Agreement”) sets forth the terms and conditions of your employment with Acasti Pharma Inc. (the "Company”), and supersedes in its entirety the Welcome Letter between you and Acasti, dated August 25, 2021. Title: Chief Executive O

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 Acasti Pha

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 09, 2024 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File N

Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update

Exhibit 99.1 Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update • Surpassed 50% Enrollment Milestone in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104 • Company Anticipates Completion of Patient Enrollment in the STRIVE-ON Trial in Late 2024 to Early 2025, with NDA Submission on Track for 1H Calendar 2025 • Projected Cash Runway into Second Calendar Quarter 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) ☐ Definitive Proxy Statem

Proxy Statement and Management Information Circular Acasti Pharma Inc. with respect to its Annual and Special Meeting of Shareholders Acasti Pharma Inc. AUTHORIZING THE CONTINUANCE, AUTHORIZING THE DOMESTICATION, APPROVAL OF 2024 EQUITY INCENTIVE PLA

TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-280536   Proxy Statement and Management Information Circular of Acasti Pharma Inc. with respect to its Annual and Special Meeting of Shareholders and Prospectus of Acasti Pharma Inc. AUTHORIZING THE CONTINUANCE, AUTHORIZING THE DOMESTICATION, APPROVAL OF 2024 EQUITY INCENTIVE PLAN, ELECTION OF DIRECTORS, INDEPENDENT REGISTERED

Exhibit 99.1

Exhibit 99.1

As filed with the Securities and Exchange Commission on July 31, 2024

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 31, 2024 Registration No.

[Signature page follows]

July 31, 2024 CORRESPONDENCE FILED VIA EDGAR Office of Life Sciences Division of Corporation Finance U.

A. Joint Filing Agreement

EX-99.A 2 tm2419166d1ex99-a.htm EXHIBIT A EXHBIIT A JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the shares of common stock, no par value, of Acasti Pharma Inc. dated as of July 10, 2024 is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions

ACST / Acasti Pharma Inc. / ADAR1 Capital Management, LLC - SC 13G Passive Investment

SC 13G 1 tm2419166d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ACASTI PHARMA INC. (Name of Issuer) Class A Common Stock, no par value (Title of Class of Securities) 00430K865 (CUSIP Number) June 28, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate

LETTER

July 3, 2024 Prashant Kohli Chief Executive Officer Acasti Pharma Inc. 103 Carnegie Center, Suite 300 Princeton, NJ 08540 Re: Acasti Pharma Inc. Registration Statement on Form S-4 Filed June 27, 2024 File No. 333-280536 Dear Prashant Kohli: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for accel

Calculation of Filing Fee Tables Form S-4 (Form Type) Acasti Pharma Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) Acasti Pharma Inc.

ACASTI PHARMA INC. 2024 EQUITY INCENTIVE PLAN Nonqualified STOCK OPTION AGREEMENT COVER SHEET

Exhibit 10.4 Grant No. ACASTI PHARMA INC. 2024 EQUITY INCENTIVE PLAN Nonqualified STOCK OPTION AGREEMENT COVER SHEET Acasti Pharma Inc., a Delaware corporation (the “Company”), hereby grants an option (the “Option”) to purchase shares of its common stock, par value $0.0001 per share (the “Common Stock”), to the Grantee named below, subject to the vesting and other conditions set forth below (the “

INDEMNIFICATION AGREEMENT

Exhibit 10.1 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of , 20 by and between Acasti Pharma Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement. RECITALS WHEREAS, the Board of Directors of the C

ACASTI PHARMA INC. 2024 EQUITY INCENTIVE PLAN Incentive STOCK OPTION AGREEMENT COVER SHEET

Exhibit 10.3 Grant No. ACASTI PHARMA INC. 2024 EQUITY INCENTIVE PLAN Incentive STOCK OPTION AGREEMENT COVER SHEET Acasti Pharma Inc., a Delaware corporation (the “Company”), hereby grants an option (the “Option”) to purchase shares of its common stock, par value $0.0001 per share (the “Common Stock”), to the Grantee named below, subject to the vesting and other conditions set forth below (the “Cov

Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial

Exhibit 99.1 Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial Company Anticipates Completion of Patient Enrollment in the STRIVE-ON Trial in Late 2024 to Early 2025, with Potential NDA Submission on Track for 1H Calendar 2025 Princeton, NJ, June 27, 2024 (GLOBE NEWSWIRE)- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma comp

Exhibit 99.1

Exhibit 99.1

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Num

As filed with the Securities and Exchange Commission on June 27, 2024

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 27, 2024 Registration No.

Acasti Pharma Inc. Incentive Compensation Recoupment Policy

Exhibit 97.1 Acasti Pharma Inc. Incentive Compensation Recovery Policy Adopted by the Board of Directors (the “Board”) of Acasti Pharma Inc. (the “Company”) on November 10, 2023 The Company is committed to conducting business in accordance with the highest ethical and legal standards, and the Board believes that a culture that emphasizes integrity and accountability is in the best interests of the

Acasti Announces Year-End 2024 Financial Results, Provides Business Update

Exhibit 99.1 Acasti Announces Year-End 2024 Financial Results, Provides Business Update • Patient Enrollment in Pivotal STRIVE-ON Phase 3 Safety Trial for GTX-104 On-Track for Potential NDA Submission in 1H Calendar 2025 • Projected Cash Runway into Second Calendar Quarter 2026 Princeton, NJ, June 21, 2024 (GLOBE NEWSWIRE)- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, b

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2024 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 ACASTI PHARMA INC

List of Subsidiaries

Exhibit 21.1 Acasti Pharma Inc. LIST OF SUBSIDIARIES Name Jurisdiction of Incorporation Percent Owned Acasti Pharma U.S., Inc. New Jersey, United States 100%

ACST / Acasti Pharma Inc. / HIRSCHMAN ORIN Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Acasti Pharma Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00430K865 (CUSIP Number) March 27, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed ☐ Rule 1

Company Overview NASDAQ: ACST April 2024

Company Overview NASDAQ: ACST April 2024 Forward Looking Statements Statements in this presentation that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 01, 2024 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Nu

CA00430K8656 / ACASTI PHARMA INC / BANK OF AMERICA CORP /DE/ Passive Investment

SC 13G 1 doc1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. N/A)* Acasti Pharma Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00430K865 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan

BANK OF AMERICA CORPORATION LIMITED POWER OF ATTORNEY

EX-99 2 bacpoa.htm BANK OF AMERICA CORPORATION LIMITED POWER OF ATTORNEY BANK OF AMERICA CORPORATION, a Delaware corporation (the "Corporation"), does hereby make, constitute, and appoint each of Szabina Biro, Hannah Chae, Andres Ortiz Custodio, Kamil Dziedzic, Krishnan Harihanran, Kelvin Kwok, Frank Lui, James Todd, Michelle Wong, and Monica Yako as an attorney-in-fact for the Corporation acting

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights

Exhibit 99.1 Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights • Projected Cash Runway Extends into Second Calendar Quarter 2026, Well Beyond Potential 1H 2025 Submission of GTX-104 New Drug Application (NDA) • Patient Enrollment in Pivotal STRIVE-ON Phase 3 Trial Continues, On Track for NDA Submission Timeline • Poster Highlighting the STRIVE-ON Trial Presented

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2024 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 Acasti

Offer Letter by and between Robert J. DelAversano and the Company, dated November 21, 2023 (incorporated by reference to Exhibit 10.1 from Form 8-K (File No. 001-35776) filed with the Commission on January 8, 2024)

November 20, 2023 PRIVATE AND CONFIDENTIAL DELIVERED BY EMAIL Robert DelAversano Dear Robert: We are pleased to extend the following offer of employment with Acasti Pharma Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 05, 2024 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File

Letter from Ernst & Young LLP (Canada), dated December 15, 2023.

Ernst & Young s.r.l./S.E.N.C.R.L. Ernst & Young LLP 900, boul. De Maisonneuve Ouest Bureau 2300 Montréal (Québec) H3A 0A8 Tél./Tel : +1 514 875 6060 Téléc./Fax : +1 514 879 2600 ey.com December 15, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read Item 4.01 of Form 8-K dated December 15, 2023, of Acasti Pharma Inc. and are in agreement with

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File

Acasti Announces Second Quarter 2024 Financial Results and Business Highlights

Exhibit 99.1 Acasti Announces Second Quarter 2024 Financial Results and Business Highlights • Announced Dosing of First Patient in Pivotal STRIVE-ON Phase 3 Randomized Trial for GTX-104 • Completed $7.5 Million Private Placement Equity Financing led by ADAR1 Partners, LP, Providing Funding Well Beyond Anticipated Submission of GTX-104 New Drug Application (NDA) • Highlighted the Potential of GTX-1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 Acast

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File

Settlement Agreement, dated October 18, 2023, by and between the Company and Aker BioMarine Antarctic AS. (incorporated by reference to Exhibit 10.1 from Form 8-K (File No. 001-35776) filed with the Commission on October 23, 2023)

Exhibit 10.1 SETTLEMENT AGREEMENT This Settlement Agreement (the “Settlement Agreement”) is entered into as of October 18, 2023 by and between (1) Acasti Pharma Inc., a corporation organized and existing under the laws of Québec, Canada, with its principal place of business located at 2572 boul. Daniel-Johnson, 2nd Floor, Laval, Québec, Canada H7T 2R3 (“Acasti”), and (2) Aker BioMarine Antarctic A

Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial

Exhibit 99.1 Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial • With achievement of enrollment milestone, pivotal STRIVE-ON safety trial on track for potential NDA submission anticipated to occur in the first half of calendar 2025 • Recently announced $7.5 million private placement financing extends projected cash runway to the first calendar quarter of 2026 PRINCETON, N.J., Oct

6,594,615 Common Shares

PROSPECTUS Filed pursuant to Rule 424(b)(3) Registration No. 333-274899 6,594,615 Common Shares The selling shareholders (the “Selling Shareholders”) named in this prospectus may use this prospectus to offer and resell from time to time up to 6,594,615 of our common shares, no par value per share, which are comprised of (i) 1,951,371 common shares (the “Shares”), (ii) 2,106,853 common shares (the

ACASTI PHARMA INC. 2572 boul. Daniel-Johnson. 2nd Floor Laval, Québec, Canada H7T 2R3

ACASTI PHARMA INC. 2572 boul. Daniel-Johnson. 2nd Floor Laval, Québec, Canada H7T 2R3 October 12, 2023 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Joshua Gorsky Re: Acasti Pharma Inc. Registration Statement on Form S-3 Filed October 6, 2023 File No. 333-274899 Request for Acceleration of E

LETTER

United States securities and exchange commission logo October 12, 2023 Brian Ford Interim Chief Financial Officer Acasti Pharma Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File

Articles of Incorporation, as amended (incorporated by reference to Exhibit 4.1 from Form S-3 (File No. 333-274899) filed with the Commission on October 6, 2023)

UNOFFICIAL TRANSLATION PREPARED BY OSLER Exhibit 4.1 CERTIFICATE OF AMENDMENT Business Corporations Act (CQLR, chapter S-31.1) I attest that the legal person ACASTI PHARMA INC. has modified its articles pursuant to the Business Corporations Act (Québec) to integrate the changes outlined in the attached articles. July 10, 2023 at 12:01 a.m. Filed in the register on July 4, 2023 under the Québec Reg

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Acasti Pharma Inc.

As filed with the Securities and Exchange Commission on October 6, 2023

As filed with the Securities and Exchange Commission on October 6, 2023 Registration Statement No.

Acasti Announces $7.5 Million Private Placement Equity Financing

EX-99.1 Acasti Announces $7.5 Million Private Placement Equity Financing Princeton, NJ, September 26, 2023 (GLOBE NEWSWIRE)- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that i

Form of Pre-Funded Warrant, dated September 25, 2023 (incorporated by reference to Exhibit 4.2 from Form 8-K (File No. 001-35776) filed with the Commission on September 26, 2023)

EX-4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission Fil

Form of Securities Purchase Agreement, dated September 24, 2023, by and between the Company and each of the Purchasers signatory thereto (incorporated by reference to Exhibit 10.1 from Form 8-K (File No. 001-35776) filed with the Commission on September 26, 2023)

EX-10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 24, 2023, between Acasti Pharma Inc., a corporation incorporated under the Business Corporations Act (Québec) (formerly Part 1A of the Companies Act (Québec)) and domiciled in Canada (the “Company”), and each purchaser identified on the signature pages hereto (each, including its su

Form of Common Warrant, dated September 25, 2023 (incorporated by reference to Exhibit 4.1 from Form 8-K (File No. 001-35776) filed with the Commission on September 26, 2023)

EX-4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

Filing Fee Table

Exhibit 107 Calculation of Filing Fees Table Form S-8 (Form Type) Acasti Pharma Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

As filed with the Securities and Exchange Commission on August 25, 2023

As filed with the Securities and Exchange Commission on August 25, 2023 Registration No.

Amended and Restated General By-Law (incorporated by reference to Exhibit 3.4 from Form 10-Q (File No. 001-35776) filed with the Commission on August 11, 2023)

Exhibit 3.4 GENERAL BY-LAW 2020-1 OF ACASTI PHARMA INC. (the “Corporation”) DOCPROPERTY "DocsID" \* MERGEFORMAT LEGAL1:62166140.2 TABLE OF CONTENTS 1 - DEFINITIONS 1 1.1 Definitions 1 1.2 Interpretation 1 1.3 Execution in Counterpart, by Facsimile and by Electronic Signature 1 2 - GENERAL BUSINESS 2 2.1 Head Office 2 2.2 Establishment 2 2.3 Seal 2 2.4 Fiscal Year 2 2.5 Execution of Instruments 2 2

Acasti Announces First Quarter 2024 Financial Results and Business Highlights

Exhibit 99.1 Acasti Announces First Quarter 2024 Financial Results and Business Highlights • New leadership team singularly focused on executing GTX-104 strategy • Announced alignment with the U.S. Food and Drug Administration (FDA) for Pivotal STRIVE-ON Phase 3 Safety Trial for GTX-104 with first patient expected to be dosed prior to the end of 2023 • Cash and cash equivalents as of quarter end w

Form of Stock Option Agreement for Employees under the Acasti Pharma Inc. Stock Option Plan

Exhibit 10.1 ACASTI PHARMA INC. STOCK OPTION PLAN AS AMENDED SEPTEMBER 28, 2022 OPTION AGREEMENT (the “Option Agreement”) Acasti Pharma Inc. (the “Company”) hereby grants the following Options to you subject to the terms and conditions of this Option Agreement, together with the provisions of the Company’s Stock Option Plan as amended September 28, 2022 (the “Plan”), all the terms of which Plan ar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 Acasti Pha

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File N

Form of Stock Option Agreement for Non-Employee Directors under the Acasti Pharma Inc. Stock Option Plan (incorporated by reference to Exhibit 10.2 from Form 10-Q (File No. 001- 35776) filed with the Commission on August 11, 2023)

Exhibit 10.2 ACASTI PHARMA INC. STOCK OPTION PLAN AS AMENDED SEPTEMBER 28, 2022 OPTION AGREEMENT (the “Option Agreement”) Acasti Pharma Inc. (the “Company”) hereby grants the following Options to you subject to the terms and conditions of this Option Agreement, together with the provisions of the Company’s Stock Option Plan as amended September 28, 2022 (the “Plan”), all the terms of which Plan ar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Num

Acasti Pharma Announces 1-for-6 Reverse Stock Split

EX 99.1 Acasti Pharma Announces 1-for-6 Reverse Stock Split LAVAL, Québec, July 7, 2023 - Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that the Company will effect a 1-for-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 04, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Num

Articles of Amendment of Acasti Pharma Inc., filed with the Registraire des entreprises du Québec on July 4, 2023 (English translation) (incorporated by reference to Exhibit 3.1 from Form 8-K (File No. 001-35776) filed with the Commission on July 7, 2023)

EX 3.1 CERTIFICATE OF AMENDMENT Business Corporations Act (CQLR, chapter S-31.1) I attest that the legal person ACASTI PHARMA INC. has modified its articles pursuant to the Business Corporations Act (Québec) to integrate the changes outlined in the attached articles. July 10, 2023 at 12:01 a.m. Filed in the register on July 4, 2023 under the Québec Registration Number 1160589793. (Signed) Registra

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 05, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Num

Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023 STRIVE-ON is the pivotal Phase 3 trial of GTX-104 to evaluate its comparable safety

Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023 STRIVE-ON is the pivotal Phase 3 trial of GTX-104 to evaluate its comparable safety and tolerability profile relative to oral nimodipine in patients hospitalized with aSAH GTX-104 has been administered in over 150 healthy volunteers to-date and has demonstrated comparable safety profile to oral nimodipine Company confirms its projected cash runway through a potential GTX-104 New Drug Application (NDA) submission in the first half of calendar 2025 LAVAL, QC, July 5, 2023 /PRNewswire/ - Acasti Pharma Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 ACASTI PHARMA INC

Acasti Pharma Reports Fiscal Year 2023 Operational Results

Acasti Pharma Reports Fiscal Year 2023 Operational Results LAVAL, Québec, June 23, 2023 /PRNewswire/ - Acasti Pharma Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Acasti Announces Appointment of Prashant Kohli as CEO

Acasti Announces Appointment of Prashant Kohli as CEO LAVAL, Québec, April 4, 2023 - Acasti Pharma Inc.

Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND Company expects the first patient to be enrolled during the second half of 2023

Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND Company expects the first patient to be enrolled during the second half of 2023 LAVAL, Québec, April 4, 2023 - Acasti Pharma Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 04, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange Acasti also confirms no exposure to Silicon Valley Bank (“SVB”) or Silvergate Bank

Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange Acasti also confirms no exposure to Silicon Valley Bank (“SVB”) or Silvergate Bank LAVAL, Québec, March 13, 2023 – Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST) a late-stage, specialty pharma company advancing three clinical stage drug candidates ad

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Letter from KPMG LLP dated February 22, 2023

KPMG LLP Tour KPMG, Suite 1500 600 de Maisonneuve Blvd. West Montréal (Québec) H3A 0A3 Tel. 514-840-2100 Fax 514-840-2187 www.kpmg.ca February 22, 2023 Securities and Exchange Commission Washington, D.C. 20549 Ladies and Gentlemen: We were previously principal accountants for Acasti Pharma Inc. and, under the date of June 21, 2022, we reported on the consolidated financial statements of Acasti Pha

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File

Acasti Pharma Reports Third Quarter 2023 Operational Results Company to Host Conference Call Today at 1:00pm ET

Acasti Pharma Reports Third Quarter 2023 Operational Results Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, February 14, 2023 - Acasti Pharma Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 Acasti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2022 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2022 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 Acast

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File

Acasti Pharma Reports Second Quarter 2023 Operational Results Company to Host Conference Call Today at 1:00pm ET

Acasti Pharma Reports Second Quarter 2023 Operational Results Company to Host Conference Call Today at 1:00pm ET LAVAL, Qu?bec, November 14, 2022 - Acasti Pharma Inc.

Acasti Announces Court Dismissal of Stockholder Litigation

Acasti Announces Court Dismissal of Stockholder Litigation LAVAL, Qu?bec, Sept. 30, 2022 (GLOBENEWSWIRE) ? Acasti Pharma Inc. (?Acasti? or the ?Company?) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announced today that a U.S. court has dismissed the remaining stockholder litigation filed

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2022 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission Fil

Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders

Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders Laval, Qu?bec, CANADA, September 29, 2022 ?Acasti Pharma Inc.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2022 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 Acasti Pha

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File N

Acasti Pharma Reports First Quarter 2023 Operational Results Company to Host Conference Call Today at 1:00pm ET

Acasti Pharma Reports First Quarter 2023 Operational Results Company to Host Conference Call Today at 1:00pm ET LAVAL, Qu?bec, August 11, 2022 - Acasti Pharma Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Shareholder Director Nominations

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2022 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Num

ACASTI PHARMA INC. Up to $11,050,000 Common Shares

424B3 1 atmsupplement.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-239538 PROSPECTUS SUPPLEMENT (To Prospectus Dated November 9, 2021) ACASTI PHARMA INC. Up to $11,050,000 Common Shares This prospectus supplement amends and supplements the information in our prospectus, dated November 21, 2021 (the “Prospectus”), filed pursuant to our registration statement on Form S-3 (File No.

Acasti Pharma Inc., Stock Option Plan, as amended June 24, 2021.

ACASTI PHARMA INC. STOCK OPTION PLAN THIS PLAN adopted October 8, 2008, amended on April 29, 2009, March 1, 2011, May 22, 2013, October 5, 2015, May 11, 2016, June 8, 2017, July 27, 2018, April 15, 2019, March 31, 2020, August 27, 2020 and June 24, 2021. ARTICLE 1 DEFINITIONS AND INTERPRETATION 1.1 Definitions. Where used in this Plan, unless there is something in the subject matter or context inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 ACASTI PHARMA INC

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2022 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Num

Employment Agreement with Brian Ford dated September 23, 2021.

EXECUTION VERSION EXECUTIVE EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?) is made this 1st day of [September] 2021 between ACASTI PHARMA INC.

Exhibit 4.6

DESCRIPTION OF ACASTI PHARMA INC.?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary sets forth certain material terms and provisions of Acasti Pharma Inc.?s (the ?Company?, ?Acasti?, ?our?, ?we?) securities that are registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). The following description

Acasti Pharma Reports Fiscal Year 2022 Operational Results Company to Host Conference Call Today at 1:00pm ET

Acasti Pharma Reports Fiscal Year 2022 Operational Results Company to Host Conference Call Today at 1:00pm ET For Immediate Release LAVAL, Qu?bec, June 21, 2022 (PR NEWSWIRE) - Acasti Pharma Inc.

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2022 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Bioavailability of IV GTX-104 compared favorably with the oral formulation of nimodipine, and no serious adverse events observed for GTX-104 Phase 3 remains on track to start before year-end A conference call to discuss the results scheduled for Wedn

ACASTI PHARMA ANNOUNCES POSITIVE RESULTS FOR PHARMACOKINETIC BRIDGING STUDY, WITH INTRAVENOUS GTX-104 MEETING ALL ENDPOINTS Bioavailability of IV GTX-104 compared favorably with the oral formulation of nimodipine, and no serious adverse events observed for GTX-104 Phase 3 remains on track to start before year-end A conference call to discuss the results scheduled for Wednesday May 18th at 1:00 PM Eastern Time LAVAL, Qu?bec, May 18, 2022 (GLOBE NEWSWIRE) - Acasti Pharma Inc.

Acasti Pharma Appoints Healthcare Industry Leader Michael L. Derby to its Board of Directors

Acasti Pharma Appoints Healthcare Industry Leader Michael L. Derby to its Board of Directors LAVAL, Qu?bec, March 25, 2022 (GLOBE NEWSWIRE) - Acasti Pharma Inc. (?Acasti? or the ?Company?) (Nasdaq: ACST and TSX-V: ACST) today announces that it has appointed Michael L. Derby to its Board of Directors. ?Michael is a successful pharma industry leader whose extensive involvement in drug repurposing an

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2022 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 Acasti

Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2022 Provides updates on key milestones: GTX-104 PK study remains on track for results to be reported in the first half of calendar 2022; GTX-102 and GTX-101 progressing on schedu

Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2022 Provides updates on key milestones: GTX-104 PK study remains on track for results to be reported in the first half of calendar 2022; GTX-102 and GTX-101 progressing on schedule Conference call to be held on Monday, February 14th at 1:00 p.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2022 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File

Acasti Pharma Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104 Bioavailability of GTX-104 compares favorably with the oral formulation of nimodipine; full PK study expected to report out as planned in H1’22

EXHIBIT 99.1 Acasti Pharma Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104 Bioavailability of GTX-104 compares favorably with the oral formulation of nimodipine; full PK study expected to report out as planned in H1?22 LAVAL, Qu?bec, Dec. 02, 2021 (GLOBE NEWSWIRE) - Acasti Pharma Inc. (?Acasti? or the ?Company?) (Nasdaq: ACST and TSX-V: ACST), today announced po

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2021 ACASTI PHARMA INC. (Exact name of registrant as specified in its charter) Québec, Canada 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commissi

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 ACASTI PHARMA INC. (Exact name of registrant as specified in its charter) Québec, Canada 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commiss

Acasti Pharma Announces Annual Stock Option Grants

EXHIBIT 99.1 Acasti Pharma Announces Annual Stock Option Grants LAVAL, Qu?bec, Nov. 12, 2021 (GLOBE NEWSWIRE) - Acasti Pharma Inc. (?Acasti? or the ?Company?) (Nasdaq: ACST and TSX-V: ACST), today announced the annual grant of stock options to its employees, executives and directors. An aggregate of 2,077,900 options to purchase common shares of the Company were granted under the Company?s stock o

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 ACASTI PHARMA INC. (Exact name of registrant as specified in its charter) Québec, Canada 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 Acast

Up to US$75,000,000 Common Shares

PROSPECTUS SUPPLEMENT (to Prospectus dated June 29, 2020) Filed Pursuant to Rule 424(b)(5) Registration No.

Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2022 Conference call to be held on Wednesday, November 10th at 1:00 p.m. ET

EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2022 Conference call to be held on Wednesday, November 10th at 1:00 p.m. ET LAVAL, Québec, Nov. 10, 2021 (GLOBE NEWSWIRE) - Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today provided a business update and announced its operating and financial re

Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 26, 2021 ACASTI PHARMA INC. (Exact Name of Registrant as Specified in Charter) Québec, Canada 001-35776 98-1359336 (State or Other Jurisdiction of Incorpora

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Exhibit 99.3 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the inclusion in this Form 8-K/A of Acasti Pharma, Inc. to be filed on or about November 5, 2021 and to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-239538) and on Form S-8 (No. 333-191383 and No. 333-227476) of Acasti Pharma, Inc. of our report dated March 26, 2021, on our aud

Acasti Pharma Provides Update Following Acquisition of Grace Therapeutics and Regains Compliance with Nasdaq Listing Standards

EXHIBIT 99.1 Acasti Pharma Provides Update Following Acquisition of Grace Therapeutics and Regains Compliance with Nasdaq Listing Standards LAVAL, Qu?bec, Sept. 22, 2021 (GLOBE NEWSWIRE) - Acasti Pharma Inc. (?Acasti? or the ?Company?) (Nasdaq: ACST and TSX-V: ACST), today provided a business update and announced that the Nasdaq Stock Market (?Nasdaq?) has confirmed to Acasti that the Company has

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2021 ACASTI PHARMA INC. (Exact name of registrant as specified in its charter) Qu?bec, Canada 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 7

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 7, 2021 ACASTI PHARMA INC. (Exact Name of Registrant as Specified in Charter) Québec, Canada 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission

Articles of Amendment of Acasti Pharma Inc. (English translation)

Exhibit 3.1 CERTIFICATE OF AMENDMENT Business Corporations Act (CQLR, chapter S-31.1) I attest that the legal person ACASTI PHARMA INC. has modified its articles pursuant to the Business Corporations Act (Qu?bec) to integrate the changes outlined in the attached articles. August 27, 2021 Filed in the register on August 26, 2021 under the Qu?bec Registration Number 1160589793. (Signed) Registraire

VIA SEDAR

Exhibit 99.1 VIA SEDAR August 27, 2021 Autorit? des march?s financiers Alberta Securities Commission British Columbia Securities Commission Manitoba Securities Commission Ontario Securities Commission Subject: Acasti Pharma Inc. (the ?Corporation?) Report on the Voting Results, in accordance with article 11.3 of Regulation 51-102 respecting Continuous Disclosure Obligations (?Regulation 51-102?) F

Articles of Amendment (incorporated by reference to Exhibit 3.1 from Form 8-K (file No. 001-35776) filed with the Commission on August 27, 2021)

Exhibit 3.1 CERTIFICATE OF AMENDMENT Business Corporations Act (CQLR, chapter S-31.1) I attest that the legal person ACASTI PHARMA INC. has modified its articles pursuant to the Business Corporations Act (Qu?bec) to integrate the changes outlined in the attached articles. August 27, 2021 Filed in the register on August 26, 2021 under the Qu?bec Registration Number 1160589793. (Signed) Registraire

Acasti Pharma Announces Successful Completion of its Merger with Grace Therapeutics, Inc., Voting Results of its Annual and Special Meeting of Shareholders and Reverse Stock Split

Exhibit 99.2 Acasti Pharma Announces Successful Completion of its Merger with Grace Therapeutics, Inc., Voting Results of its Annual and Special Meeting of Shareholders and Reverse Stock Split LAVAL, Qu?bec, Aug. 26, 2021 (GLOBE NEWSWIRE) - Acasti Pharma Inc. (?Acasti?) (NASDAQ: ACST?TSX-V: ACST), announced today the completion of its previously disclosed acquisition of Grace Therapeutics, Inc. (?

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 8-K _____________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 26, 2021 ACASTI PHARMA INC. (Exact Name of Registrant as Specified in Charter) Québec, Canada 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission Fi

Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2022 August 4th webcast replay discussing planned acquisition of Grace Therapeutics available on the Company’s website Shareholders urged to vote in advance of upcoming shareholde

EXHIBIT 99.1 Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2022 August 4th webcast replay discussing planned acquisition of Grace Therapeutics available on the Company?s website Shareholders urged to vote in advance of upcoming shareholder meeting on August 26th LAVAL, Qu?bec, Aug. 12, 2021 (GLOBE NEWSWIRE) - Acasti Pharma Inc. (?Acasti? or the ?Company?) (Nasdaq: ACST and

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 ACASTI PHARMA INC. (Exact name of registrant as specified in its charter) Qu?bec, Canada 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 ACASTI PHARMA INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 ACASTI PHARMA INC. (Exact name of registrant as specified in its charter) Qu?bec, Canada 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 Acasti Pha

Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2022 August 4th webcast replay discussing planned acquisition of Grace Therapeutics available on the Company’s website Shareholders urged to vote in advance of upcoming shareholde

EXHIBIT 99.1 Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2022 August 4th webcast replay discussing planned acquisition of Grace Therapeutics available on the Company?s website Shareholders urged to vote in advance of upcoming shareholder meeting on August 26th LAVAL, Qu?bec, Aug. 12, 2021 (GLOBE NEWSWIRE) - Acasti Pharma Inc. (?Acasti? or the ?Company?) (Nasdaq: ACST and

Crescendo Communications, llC

Filed by Acasti Pharma Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6 under the Securities Exchange Act of 1934 Subject Company: Acasti Pharma Inc. Commission File No.: 001-35776 Crescendo Communications, llC To: Acasti and Grace Management From Crescendo Communications Subject: Acasti/Grace Acquisition Call Date: August 4, 2021 I. Introduction ?

YOUR VOTE IS IMPORTANT PLEASE VOTE YOUR PROXY TODAY

Filed by Acasti Pharma Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6 under the Securities Exchange Act of 1934 Subject Company: Acasti Pharma Inc. Commission File No.: 001-35776 YOUR VOTE IS IMPORTANT PLEASE VOTE YOUR PROXY TODAY August 4, 2021 Dear Stockholder: We are reaching out regarding the proxy materials we recently sent you in connection

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 8-K _____________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 23, 2021 ACASTI PHARMA INC. (Exact Name of Registrant as Specified in Charter) QUEBEC, CANADA 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File

Acasti Pharma Schedules Conference Call for August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics All shareholders are strongly encouraged to vote in advance of the August 26, 2021, annual and special meeting of shareholders

Exhibit 99.1 Acasti Pharma Schedules Conference Call for August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics All shareholders are strongly encouraged to vote in advance of the August 26, 2021, annual and special meeting of shareholders LAVAL, Qu?bec, July 23, 2021 (GLOBE NEWSWIRE) - Acasti Pharma Inc. (?Acasti? or the ?Company?) (Nasdaq: ACST and TSX-V: ACST) announces it

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 23, 2021 ACASTI PHARMA INC. (Exact Name of Registrant as Specified in Charter) QUEBEC, CANADA 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File

Acasti Pharma Schedules Conference Call for August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics All shareholders are strongly encouraged to vote in advance of the August 26, 2021, annual and special meeting of shareholders

Exhibit 99.1 Acasti Pharma Schedules Conference Call for August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics All shareholders are strongly encouraged to vote in advance of the August 26, 2021, annual and special meeting of shareholders LAVAL, Qu?bec, July 23, 2021 (GLOBE NEWSWIRE) - Acasti Pharma Inc. (?Acasti? or the ?Company?) (Nasdaq: ACST and TSX-V: ACST) announces it

Case 1:21-cv-06051 Document 1 Filed 07/14/21 Page 1 of 21 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK

Exhibit 99.1 Case 1:21-cv-06051 Document 1 Filed 07/14/21 Page 1 of 21 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK LAUDEN BISEL, Plaintiff, Case No.: -against- COMPLAINT ACASTI PHARMA, INC., RODERICK DEMAND FOR JURY TRIAL CARTER, JAN D?ALVISE, JOHN CANAN, and DONALD OLDS, Defendants. Plaintiff, Lauden Bisel (?Plaintiff?), by his undersigned attorneys, alleges upon personal knowledge

Case 1:21-cv-06051 Document 1 Filed 07/14/21 Page 1 of 21 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK

Exhibit 99.1 Case 1:21-cv-06051 Document 1 Filed 07/14/21 Page 1 of 21 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK LAUDEN BISEL, Plaintiff, Case No.: -against- COMPLAINT ACASTI PHARMA, INC., RODERICK DEMAND FOR JURY TRIAL CARTER, JAN D?ALVISE, JOHN CANAN, and DONALD OLDS, Defendants. Plaintiff, Lauden Bisel (?Plaintiff?), by his undersigned attorneys, alleges upon personal knowledge

Case 1:21-cv-01039-UNA Document 1 Filed 07/16/21 Page 1 of 10 PageID #: 1 UNITED STATES DISTRICT COURT DISTRICT OF DELAWARE

Exhibit 99.2 Case 1:21-cv-01039-UNA Document 1 Filed 07/16/21 Page 1 of 10 PageID #: 1 UNITED STATES DISTRICT COURT DISTRICT OF DELAWARE SEAN DAWSON, ) ) Plaintiff, ) ) Case No. v. ) ) JURY TRIAL DEMANDED ACASTI PHARMA, INC., RODERICK ) CARTER, JAN D?ALVISE, JOHN CANAN, ) DONALD OLDS, ACASTI PHARMA U.S., ) INC., and GRACE THERAPEUTICS, INC., ) ) Defendants. ) COMPLAINT FOR VIOLATION OF THE SECURIT